Assero

Assero is a pre-clinical stage biotechnology company focused on developing next-generation antibody therapeutics for oncology and ophthalmology. The company leverages a proprietary antibody discovery platform to engineer highly specific and potent biologics targeting key pathways in angiogenesis and lymphangiogenesis. Their lead programs focus on dual inhibition of VEGFR2 and VEGFR3 to address limitations in current anti-VEGF therapies for solid tumors and retinal diseases. By targeting both blood and lymphatic vessel growth, Assero aims to provide more comprehensive treatment options for patients with resistant or refractory conditions.